Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 1957-1971

  Wachsberger, Phyllis ^a,b   Burd, Randy ^a   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; MONOCLONAL ANTIBODY DC101; N ACETYLCOLCHINOL PHOSPHATE; SEMAXANIB; TNP 40; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB; ZK 222548;

ANGIOGENESIS; APOPTOSIS; BLEEDING; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CYCLE; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; HYPOXIA; IONIZING RADIATION; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOSIS; TOXICITY; TREATMENT OUTCOME; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0038176480     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Owen, J. B., Coia, L. R., and Hanks, G. E. Recent patterns of growth in radiation therapy facilities in the United States: a patterns of care study report. Int. J. Radiat. Oncol. Biol. Phys., 24: 983-986, 1992.
2. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst. (Bethesda), 88: 1193-1203, 1996.
3. Strafford, I. J. Concepts and developments in radiosensitization of mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 22: 529-532, 1992.
4. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays, 13: 31-36, 1991.
5. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
6. Camphausen, K., and Menard, C. Angiogenesis inhibitors and radiotherapy of primary tumours. Expert Opin. Biol. Ther., 2: 477-481, 2002.
7. Scappaticci, F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol., 20: 3906-3927, 2002.
8. Kerbel, R., and Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2: 727-739, 2002.
9. Gorski, D. H., Mauceri, H. J., Salloum, R. M., Gately, S., Hellman, S., Beckett, M. A., Sukhatme, V. P., Soff, G. A., Kufe, D. W., and Weichselbaum, R. R. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res., 58: 5686-5689, 1998.
10. Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., and Weichselbaum, R. R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res., 59: 3374-3378, 1999.
11. Mauceri, H. J., Hanna, N. N., Wayne, J. D., Hallahan, D. E., Hellman, S., and Weichselbaum, R. R. Tumor necrosis factor α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res., 56: 4311-4314, 1996.
12. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
13. Griffin, R. J., Williams, B. W., Wild, R., Cherrington, J. M., Park, H., and Song, C. W. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res., 62: 1702-1706, 2002.
14. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., and Boucher, Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res., 60: 5565-5570, 2000.
15. Teicher, B. A., Holden, S. A., Ara, G., Dupuis, N. P., Liu, F., Yuan, J., Ikebe, M., and Kakeji, Y. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int. J. Cancer, 61: 732-737, 1995.
16. Teicher, B. A., Williams, J. I., Takeuchi, H., Ara, G., Herbst, R. S., and Buxton, D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res., 18: 2567-2573, 1998.
17. Folkman, J. The vascularization of tumors. Sci. Am., 234: 58-64, 70-73, 1976.
18. Thomlinson, R., and Gray, L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 9: 539-549, 1955.
19. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
20. Los, M., and Voest, E. E. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin. Oncol., 28: 93-105, 2001.
21. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
22. Ferrara, N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol., 280: C1358-C1366, 2001.
23. Asano, M., Yukita, A., Matsumoto, T., Kondo, S., and Suzuki, H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res., 55: 5296-5301, 1995.
24. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Investig., 103: 159-165, 1999.
25. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Wash. DC), 246: 1306-1309, 1989.
26. Bellamy, W. T., Richter, L., Frutiger, Y., and Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res., 59: 728-733, 1999.
27. Bertolini, F., Mancuso, P., Gobbi, A., and Pruneri, G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp. Hematol., 28: 993-1000, 2000.
28. Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N., Stockschlader, M., and Hossfeld, D. K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89: 1870-1875, 1997.
29. Levy, A. P., Levy, N. S., Wegner, S., and Goldberg, M. A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem., 270: 13333-13340, 1995.
30. Shweiki, D., Neeman, M., Itin, A., and Keshet, E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. USA, 92: 768-772, 1995.
31. Ellis, L. M., Staley, C. A., Liu, W., Fleming, R. Y., Parikh, N. U., Bucana, C. D., and Gallick, G. E. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem., 273: 1052-1057, 1998.
32. Mukhopadhyay, D., Tsiokas, L., Zhou, X. M., Foster, D., Brugge, J. S., and Sukhatme, V. P. Hypoxic inductibn of human vascular endothelial growth factor expression through c-Src activation. Nature (Lond.), 375: 577-581, 1995.
33. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA, 94: 8104-8109, 1997.
34. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
35. Jung, Y. D., Nakano, K., Liu, W., Gallick, G. E., and Ellis, L. M. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res., 59: 4804-4807, 1999.
36. Rak, J., and Kerbel, R. S. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol., 333: 267-283, 2001.
37. Takahashi, Y., Bucana, C. D., Cleary, K. R., and Ellis, L. M. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int. J. Cancer, 79: 34-38, 1998.
38. Koukourakis, M. I. Tumour angiogenesis and response to radiotherapy. Anticancer Res., 21: 4285-4300, 2001.
39. Vaupel, P. W. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin. Paediatr., 209: 243-249, 1997.
40. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. Genes expressed in human tumor endothelium. Science (Wash. DC), 289: 1197-1202, 2000.
41. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., and Augustin, H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res., 60: 1388-1393, 2000.
42. Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res., 48: 2641-2658, 1988.
43. Less, J. R., Skalak, T. C., Sevick, E. M., and Jain, R. K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res., 51: 265-273, 1991.
44. Jain, R. K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng., 1: 241-263, 1999.
45. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 7: 987-989, 2001.
46. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology, 60: 634-639, 2002.
47. Reinmuth, N., Stoeltzing, O., Liu, W., Ahmad, S. A., Jung, Y. D., Fan, F., Parikh, A., and Ellis, L. M. Endothelial survival factors as targets for antineoplastic therapy. Cancer J., 7 (Suppl. 3): S109-S119, 2001.
48. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, K., Pissakas, G., Gatter, K. C., and Harris, A. L. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res., 21: 4301-4309, 2001.
49. Chapman, J. D., Dugle, D. L., Reuvers, A. P., Meeker, B. E., and Borsa, J. Studies on the radiosensitizing effect of oxygen in Chinese hamster cells. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 26: 383-389, 1974.
50. Moore, J. V. Re: Tumor cure studies on the rat sarcoma BA1112 using continuous low-dose-rate radiation. Radiology, 155: 837-838, 1985.
51. Tannock, I. F., and Hill, R. P. The Basic Science of Oncology, 3rd ed. McGraw-Hill, 1998.
52. Evans, S. M., Hahn, S. M., Magarelli, D. P., and Koch, C. J. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am. J. Clin. Oncol., 24: 467-472, 2001.
53. Rockwell, S., and Moulder, J. E. Hypoxic fractions of human tumors xenografted into mice: a review. Int. J. Radiat. Oncol. Biol. Phys., 19: 197-202, 1990.
54. Tannock, I. F. Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br. J. Radiol., 45: 515-524, 1972.
55. Wouters, B. G., and Brown, J. M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res., 147: 541-550, 1997.
56. Brown, J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol., 52: 650-656, 1979.
57. Chaplin, D. J., and Hill, S. A. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br. J. Cancer, 71: 1210-1213, 1995.
58. Sutherland, R. M., and Franko, A. J. On the nature of the radiobiologically hypoxic fraction in tumors. Int. J. Radiat. Oncol. Biol. Phys., 6: 117-120, 1980.
59. Giaccia, A. J. Hypoxic stress proteins: survival of the fittest. Semin. Radiat. Oncol., 6: 46-58, 1996.
60. Jung, Y. D., Ahmad, S. A., Liu, W., Reinmuth, N., Parikh, A., Stoeltzing, O., Fan, F., and Ellis, L. M. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin. Cancer Biol., 12: 105-112, 2002.
61. Rak, J., Yu, J. L., Kerbel, R. S., and Coomber, B, L. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res., 62: 1931-1934, 2002.
62. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., and Livingston, D, M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med., 6: 1335-1340, 2000.
63. Bowers, G., Reardon, D., Hewitt, T., Dent, P., Mikkelsen, R. B., Valerie, K., Lammering, G., Amir, C., and Schmidt-Ullrich, R. K. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene, 20: 1388-1397, 2001.
64. Hendry, J. H. Treatment acceleration in radiotherapy: the relative time factors and dose-response slopes for tumours and normal tissues. Radiother. Oncol., 25: 308-312, 1992.
65. Hansen-Algenstaedt, N., Stoll, B. R., Padera, T. P., Dolmans, D. E., Hicklin, D. J., Fukumura, D., and Jain, R. K. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res., 60: 4556-4560, 2000.
66. Teicher, B. A. Hypoxia and drug resistance. Cancer Metastasis Rev., 13: 139-168, 1994.
67. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
68. Geng, L., Donnelly, E., McMahon, G., Lin, P. C., Sierra-Rivera, E., Oshinka, H., and Hallahan, D. E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res., 61: 2413-2419, 2001.
69. Griscelli, F., Li, H., Cheong, C., Opolon, P., Bennaceur-Griscelli, A., Vassal, G., Soria, J., Soria, C., Lu, H., Perricaudet, M., and Yeh, P. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. USA, 97: 6698-6703, 2000.
70. Hess, C., Vuong, V., Hegyi, I., Riesterer, O., Wood, J., Fabbro, D., Glanzmann, C., Bodis, S., and Pruschy, M. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer, 85: 2010-2016, 2001.
71. Huang, S. M., Li, J., Armstrong, E. A., and Harari, P. M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res., 62: 4300-4306, 2002.
72. Kozin, S. V., Boucher, Y., Hicklin, D. J., Bohlen, P., Jain, R. K., and Suit, H. D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res., 61: 39-44, 2001.
73. Lund, E. L., Bastholm, L., and Kristjansen, P. E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin. Cancer Res., 6: 971-978, 2000.
74. Milas, L., Kishi, K., Hunter, N., Mason, K., Masferrer, J. L., and Tofilon, P. J. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. (Bethesda), 91: 1501-1504, 1999.
75. Murata, R., Nishimura, Y., and Hiraoka, M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 37: 1107-1113, 1997.
76. Asano, M., Yukita, A., and Suzuki, H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn. J. Cancer Res., 90: 93-100, 1999.
77. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P., and Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res., 59: 5209-5218, 1999.
78. Hill, S. A., Smith, K. A., Williams, K. B., and Denekamp, J. The fractionated response of mouse stroma after X-rays and neutrons: influence of early versus late expression of damage, Radiother. Oncol., 16: 129-137, 1989.
79. Teicher, B. A., Emi, Y., Kakeji, Y., and Northey, D. TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur. J. Cancer, 32A: 2461-2466, 1996.
80. Dicker, A. P., Williams, T. L., and Grant, D, S. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am. J. Clin. Oncol., 24: 438-442, 2001.
81. Kishi, K., Milas, L., Hunter, N., and Sato, M. Recent studies on anti-angiogenesis in cancer therapy. Nippon Rinsho, 58: 1747-1762, 2000.
82. Milas, L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol., 11: 290-299, 2001.
83. Pyo, H., Choy, H., Amorino, G. P., Kim, J. S., Cao, Q., Hercules, S. K., and DuBois, R. N. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res., 7: 2998-3005, 2001.
84. Nasu, S., Ang, K. K., Fan, Z., and Milas, L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys., 51: 474-477, 2001.
85. Folkman, J., and Camphausen, K. Cancer. What does radiotherapy do to endothelial cells? Science (Wash, DC), 293: 227-228, 2001.
86. Gupta, V. K., Jaskowiak, N. T., Beckett, M. A., Mauceri, H. J., Grunstein, J., Johnson, R. S., Calvin, D. A., Nodzenski, E., Pejovic, M., Kufe, D. W., Posner, M. C., and Weichselbaum, R. R. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J., 8: 47-54, 2002.
87. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
88. Teicher, B. A., Holden, S. A., Dupuis, N. P., Kakeji, Y., Ikebe, M., Emi, Y., and Goff, D. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat., 36: 227-236, 1995.
89. Shaheen, R. M., Tseng, W. W., Davis, D. W., Liu, W., Reinmuth, N., Vellagas, R., Wieczorek, A. A., Ogura, Y., McConkey, D. J., Drazan, K. E., Bucana, C. D., McMahon, G., and Ellis, L. M. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res., 61: 1464-1468, 2001.
90. Wahl, M. L., and Grant, D. S. Effects of microenvironmental extracellular pH and extracellular matrix proteins on angiostatin's activity and on intracellular pH. Gen. Pharmacol., 35: 277-285, 2000.
91. Moser, T. L., Stack, M. S., Wahl, M. L., and Pizzo, S. V. The mechanism of action of angiostatin: can you teach an old dog new tricks? Thromb. Haemostasis, 87: 394-401, 2002.
92. Milas, L., and Hanson, W. R. Eicosanoids and radiation. Eur. J. Cancer, 31A: 1580-1585, 1995.
93. Mehrabi, M. R., Serbecic, N., Tamaddon, F., Kaun, C., Huber, K., Pacher, R., Wild, T., Mall, G., Wojta, J., and Glogar, H. D. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc. Res., 56: 214-224, 2002.
94. Furuta, Y., Hunter, N., Barkley, T., Jr., Hall, E., and Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res., 48: 3008-3013, 1988.
95. Kishi, K., Petersen, S., Petersen, C., Hunter, N., Mason, K., Masferrer, J. L., Tofilon, P. J., and Milas, L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res., 60: 1326-1331, 2000.
96. Petersen, C., Petersen, S., Milas, L., Lang, F. F., and Tofilon, P. J. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin. Cancer Res., 6: 2513-2520, 2000.
97. Milas, L., Akimoto, T., Hunter, N. R., Mason, K. A., Buchmiller, L., Yamakawa, M., Muramatsu, H., and Ang, K. K. Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int. J. Radiat. Oncol. Biol. Phys., 52: 514-521, 2002.
98. Emoto, M., Iwasaki, H., Mimura, K., Kawarabayashi, T., and Kikuchi, M. Differences in the angiogenesis of benign and malignant ovarian tumors, demonstrated by analyses of color Doppler ultrasound, immunohistochemistry, and microvessel density. Cancer (Phila.), 80: 899-907, 1997.
99. Kakolyris, S., Giatromanolaki, A., Koukourakis, M., Leigh, I. M., Georgoulias, V., Kanavaros, P., Sivridis, E., Gatter, K. C., and Harris, A. L. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Cancer Res., 59: 5602-5607, 1999.
100. Kakolyris, S., Fox, S. B., Koukourakis, M., Giatromanolaki, A., Brown, N., Leek, R. D., Taylor, M., Leigh, I. M., Gatter, K. C., and Harris, A. L. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br. J. Cancer, 82: 844-851, 2000.
101. Milosevic, M. F., Fyles, A. W., Wong, R., Pintilie, M., Kavanagh, M. C., Levin, W., Manchul, L. A., Keane, T. J., and Hill, R. P. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer (Phila.), 82: 2418-2426, 1998.
102. Boucher, Y., Lee, I., and Jain, R. K, Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc. Res., 50: 175-182, 1995.
103. , Papetti, M., and Herman, I. M. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol Cell Physiol., 282: C947-C970, 2002.
104. Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol., 237: 97-132, 1999.
105. Dunst, J., Hansgen, G., Lautenschlager, C., Fuchsel, G., and Becker, A. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. Int. J. Radiat. Oncol. Biol. Phys., 43: 367-373, 1999.
106. Busse, M., and Vaupel, P. W. The role of tumor volume in "reoxygenation" upon cyclophosphamide treatment. Acta Oncol., 34: 405-408, 1995.
107. Rofstad, E. K. Hypoxia and reoxygenation in human melanoma xenografts. Int. J. Radiat. Oncol. Biol. Phys., 17: 81-89, 1989.
108. Olive, P. L. Radiation-induced reoxygenation in the SCCVII murine tumour: evidence for a decrease in oxygen consumption and an increase in tumour perfusion. Radiother. Oncol., 32: 37-46, 1994.
109. Mayr, N. A., Yuh, W. T., Magnotta, V. A., Ehrhardt, J. C., Wheeler, J. A., Sorosky, J. I., Davis, C. S., Wen, B. C., Martin, D. D., Pelsang, R. E., Buller, R. E., Oberley, L. W., Mellenberg, D. E., and Hussey, D. H. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int. J. Radiat. Oncol. Biol. Phys., 36: 623-633, 1996.
110. Wartenberg, M., Donmez, F., Ling, F. C., Acker, H., Hescheler, J., and Sauer, H. Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. FASEB J., 15: 995-1005, 2001.
111. Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., and Jain, R. K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA, 93: 14765-14770, 1996.
112. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.
113. Kirsch, M., Strasser, J., Allende, R., Bello, L., Zhang, J., and Black, P. M. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res., 58: 4654-4659, 1998.
114. Wassberg, E., Hedborg, F., Skoldenberg, E., Stridsberg, M., and Christofferson, R. Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am. J. Pathol., 154: 395-403, 1999.
115. Masood, R., Cai, J., Zheng, T., Smith, D. L., Hinton, D. R., and Gill, P. S. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood, 98: 1904-1913, 2001.
116. Denekamp, J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev., 9: 267-282, 1990.
117. Siemann, D. W. Vascular targeting agents. Horiz. Cancer Ther., 3: 4-15, 2002.
118. Ching, L. M., Joseph, W. R., and Baguley, B. C. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br. J. Cancer, 66: 128-130, 1992.
119. Cliffe, S., Taylor, M. L., Rutland, M., Baguley, B. C., Hill, R. P., and Wilson, W. R. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int. J. Radiat. Oncol. Biol. Phys., 29: 373-377, 1994.
120. Hill, S. A., Sampson, L. E., and Chaplin, D. J. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer, 63: 119-123, 1995.
121. Laws, A. L., Matthew, A. M., Double, J. A., and Bibby, M. C. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer, 71: 1204-1209, 1995.
122. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res, 57: 1829-1834, 1997.
123. Li, L., Rojiani, A., and Siemann, D. W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 42: 899-903, 1998.
124. Murata, R., Siemann, D. W., Overgaard, J., and Horsman, M. R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol., 60: 155-161, 2001.
125. Siemann, D. W., and Rojiani, A. M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys., 53: 164-171, 2002.
126. Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R., Dennis, M. F., and Chaplin, D. J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res., 59: 1626-1634, 1999.
127. Horsman, M. R., Ehrnrooth, E., Ladekarl, M., and Overgaard, J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int. J. Radiat. Oncol. Biol. Phys., 42: 895-898, 1998.
128. Ching, L. M., Joseph, W. R., Crosier, K. E., and Baguley, B. C. Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res., 54: 870-872, 1994.
129. Mahadevan, V., Malik, S. T., Meager, A., Fiers, W., Lewis, G. P., and Hart, I. R. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res., 50: 5537-5542, 1990.
130. Philpott, M., Baguley, B. C., and Ching, L. M. Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol., 36: 143-148, 1995.
131. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72: 3666-3670, 1975.
132. Galbraith, S. M., Chaplin, D. J., Lee, F., Stratford, M. R., Locke, R. J., Vojnovic, B., and Tozer, G. M. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res., 21: 93-102, 2001.
133. Chaplin, D. J., Pettit, G. R., and Hill, S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res., 19: 189-195, 1999.
134. Paris, F., Fuks, Z., Kang, A., Capodieci, P., Juan, G., Ehleiter, D., Haimovitz-Friedman, A., Cordon-Cardo, C., and Kolesnick, R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (Wash. DC), 293: 293-297, 2001.
135. Pena, L. A., Fuks, Z., and Kolesnick, R. N. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency, Cancer Res., 60: 321-327, 2000.
136. Hall, E. J. Radiobiology for the Radiologist, 5th ed., Philadelphia: LWW, 2000.
137. Dicker, A. P., Anne, R., Bonanni, R., Sidor, C., Gubish, E., and Curran, W. J., Jr. Phase I trial results of recombinant hluman angiostatin protein (rhA) and external beam radiation therapy (EBRT). In: 38th Annual Meeting of the American Association of Clinical Oncology. Alexandria, VA: ASCO Publications, 2002.